H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Cartesian Therapeutics to $45 from $49 and keeps a Buy rating on the shares following the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Engages Investors at Conferences
- Cartesian Therapeutics Announces New Employment Inducement Grants
- Nvidia, Crowdstrike upgraded: Wall Street’s top analyst calls
- Cartesian Therapeutics initiated with a Buy at TD Cowen
- JMP Securities healthcare analysts hold an analyst/industry conference call